Ignite Creation Date:
2026-03-26 @ 3:15 PM
Ignite Modification Date:
2026-06-09 @ 4:25 AM
Study NCT ID:
NCT07365566
Status:
RECRUITING
Last Update Posted:
2026-03-03
First Post:
2026-01-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pain Assessment in Patients With Idiopathic REM Sleep Behaviour Disorder
Sponsor:
University Hospital, Toulouse
Organization:
Study Overview
Official Title:
Pain Assessment in Patients With Idiopathic REM Sleep Behaviour Disorder
Status:
RECRUITING
Status Verified Date:
2026-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PAIN-iRBD
Brief Summary:
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, with over 12 million patients expected globally by 2040. The disease is currently diagnosed at the appearance of motor symptoms, but by then, over 60% of striatal dopaminergic neurons have already been destroyed. Prodromal symptoms such as idiopathic REM Sleep Behavior Disorder (iRBD), anosmia, mood disorders and constipation appear earlier and are listed as criteria for a prodromal PD diagnosis. Identifying early signs is critical to initiate neuroprotective treatments as early as possible. While pain is prevalent and highly disabling in early PD, no data are currently available on pain perception in iRBD patients, whose condition is of the main risk factor for PD development.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| ID-RCB | OTHER | 2025-A02575-44 | View |